How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biopsy Forcep Market
- By Product Type: Single-use Biopsy Forceps, Reusable Biopsy Forceps, Rotatable Biopsy Forceps, Disposable Biopsy Forceps
- By Application: Gastrointestinal Biopsy, Pulmonary Biopsy, Urological Biopsy, Gynecological Biopsy, ENT Biopsy
- By End User: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Specialty Clinics
- By Material: Stainless Steel, Titanium, Plastic Handle with Metal Jaws
- By Jaw Type: Standard Jaw, Alligator Jaw, Cup Jaw, Oval Jaw, Spike Jaw
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Single-use Biopsy Forceps leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Biopsy Forcep Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Application 5
End User 4
Material 3
Jaw Type 5
Companies profiled
Olympus Corporation
Boston Scientific Corporation
Medtronic plc
Cook Medical (a subsidiary of Medtronic)
ConMed Corporation
Richard Wolf GmbH
Stryker Corporation
Teleflex Incorporated
Smith & Nephew plc
Karl Storz GmbH & Co. KG
Pentax Medical (a division of HOYA Corporation)
Micro-Tech Endoscopy USA Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Olympus Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cook Medical (a subsidiary of Medtronic)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ConMed Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Richard Wolf GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Teleflex Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Smith & Nephew plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Karl Storz GmbH & Co. KG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Pentax Medical (a division of HOYA Corporation)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Micro-Tech Endoscopy USA Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →EndoChoice Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Medi-Globe GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BIOTRONIK SE & Co. KG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$4,600M by 2033 · 4.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Single-use Biopsy Forceps60.8
- Reusable Biopsy Forceps13.0
- Rotatable Biopsy Forceps15.2
- Disposable Biopsy Forceps11.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,101M → $1,629M · 5.0%
Europe$767.7M → $1,011M · 3.5%
Asia Pacific$700.9M → $864.4M · 2.7%
Latin America$433.9M → $539.9M · 2.8%
Middle East and Africa$333.8M → $449.0M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.052026
4.052027
4.062028
4.082029
4.082030
4.112031
4.112032
4.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Olympus Corporation23.9
- Boston Scientific Corporation24.3
- Medtronic plc4.4
- Cook Medical (a subsidiary of Medtronic)7.8
- ConMed Corporation4.9
- Richard Wolf GmbH6.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type20.3%
Application14.3%
End User24.7%
Material12.8%
Jaw Type27.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.3
- Europe22.5
- Asia Pacific19.2
- Latin America12.0
- Middle East and Africa10.0
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Olympus Corporation | 97 | 79 | 85 | 92 | 79 | 89 | 87 |
| Boston Scientific Corporation | 68 | 70 | 88 | 76 | 74 | 88 | 77 |
| Medtronic plc | 63 | 72 | 80 | 67 | 84 | 62 | 71 |
| Cook Medical (a subsidiary of Medtronic) | 71 | 76 | 63 | 69 | 81 | 76 | 73 |
| ConMed Corporation | 76 | 73 | 55 | 72 | 53 | 62 | 65 |
| Richard Wolf GmbH | 50 | 63 | 46 | 71 | 55 | 61 | 58 |
| Stryker Corporation | 54 | 62 | 42 | 51 | 56 | 63 | 55 |
| Teleflex Incorporated | 51 | 40 | 45 | 57 | 35 | 50 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Olympus Corporation
- Boston Scientific Corporation
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Olympus Corporation | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Boston Scientific Corporation | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Medtronic plc | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Cook Medical (a subsidiary of Medtronic) | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| ConMed Corporation | ◐ | ✓ | − | ◐ | ◐ | − |
| Richard Wolf GmbH | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Stryker Corporation | ◐ | − | − | ◐ | − | ✓ |
| Teleflex Incorporated | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Olympus Corporation87
2Boston Scientific Corporation77
3Cook Medical (a subsidiary of Medtronic)73
4Medtronic plc71
5ConMed Corporation65
6Richard Wolf GmbH58
7Stryker Corporation55
8Teleflex Incorporated46
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Olympus Corporation
Challenger3
Strong scale, closing on the leaders.
Boston Scientific CorporationMedtronic plcCook Medical (a subsidiary of Medtronic)
Contender2
Focused players with pockets of strength.
ConMed CorporationRichard Wolf GmbH
Niche2
Specialists in a single segment or region.
Stryker CorporationTeleflex Incorporated
Go-to-market strategy
Land Product Type in North America, then scale across Biopsy Forcep Market — a $187M beachhead inside a $3.48B market.
Beachhead (SOM)$187Mobtainable near-term
Serviceable (SAM)$1.24Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Single-use Biopsy Forceps
Best fit — highest urgency & budget in Product Type.
Economic buyer79 fit
Reusable Biopsy Forceps
Strong fit — clear ROI and a fast path to value.
End user65 fit
Rotatable Biopsy Forceps
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biopsy Forcep Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation13%
Closed-won8%
$19.3KCAC
$71KLTV
3.7:1LTV : CAC
< 5 moCAC payback
Investment thesis
Biopsy Forcep Market is a resilient opportunity — $5.50B by 2033, compounding at 3.4%.
TAM · 2025$4.20Btoday
TAM · 2033$5.50Bforecast
CAGR3.4%2027–2033
Cumulative$43.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.50BTotal addressable market
SAM$2.01BServiceable available market
SOM$387MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.50BLarge & growingTAM by 2033 at 3.4% CAGR
$2.01BServiceable nowreachable with today’s model
$387MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.29BBear2.2% CAGR
$5.50BBase3.4% CAGR
$7.04BBull4.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biopsy Forcep Market — a $2.79B market by 2033. Plan: grow share from 8.7% to 17.7%.
Market size · 2033$2.79Btotal addressable
Market CAGR8.1%2027–2033
Target share17.7%from 8.7% today
Revenue ambition$494Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 17.7% | On track |
| Revenue | $235M | $494M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.7% | 42.0% | On track |
| Customer retention | 85.6% | 94.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $66M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Biopsy Forcep Market conversation — a $6.37B market you can size, segment and defend in minutes.
Market size · 2033$6.37Btotal opportunity
Growth8.9%CAGR to 2033
Addressable buyers1,635+accounts in scope
Typical ROI4.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.3×return on cost, year one
< 2 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Olympus CorporationBoston Scientific CorporationMedtronic plcCook Medical (a subsidiary of Medtronic)ConMed CorporationRichard Wolf GmbHStryker CorporationTeleflex Incorporated+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biopsy Forcep Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biopsy Forcep Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biopsy Instrumens Market
Market size, share, segmentation and regional forecast.
$496M market · 2025 base year
View reportBiopsy Needle Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBiopsy Punches Market
Market size, share, segmentation and regional forecast.
$327M market · 2025 base year
View reportBio-Rad Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBioreactors & Fermenters Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBioremediation Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportBioresorbable (Resorbable) Polymers Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportBio-Resorbable Ceramic Market
Market size, share, segmentation and regional forecast.
$407M market · 2025 base year
View reportBio-Resorbable Pins and Screw Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportBioresorbable Polymer Market
Market size, share, segmentation and regional forecast.
$942M market · 2025 base year
View reportBIOS Firmware Technology Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBio-Safe Hand-Washing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.